REGN250117P805000
- 88.37
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value
Regeneron Pharmaceuticals Shares Are Trading Lower After Citigroup Cut Its Price Target on the Stock From $895 to $795.
Could The Market Be Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Its Attractive Financial Prospects?
Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Regeneron Pharma Is Maintained at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $565 to $1,152
Regeneron (REGN) Gets a Buy From Bernstein
Regeneron Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 5:15 PM ET
Live On CNBC, Rob Sechan Announces Sold Regeneron
Express News | Regeneron Pharmaceuticals Inc : Jefferies Cuts Target Price to $1,120 From $1,200
Citigroup Cuts Regeneron Pharmaceuticals' Price Target to $795 From $895
Regeneron Announces IPR&D Charges
4D Molecular Downgraded at BMO on Limited Population for Wet AMD Candidate
Regeneron Pharmaceuticals Met Primary Endpoint in Cell Carcinoma Treatment Trial
Express News | Regeneron Pharmaceuticals Shares Down 3.9% Premarket
Regeneron Stock Falls on Eylea Sales Miss